HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Congestion Continues In Private Label Mucinex Pipeline; Court Rules Against Mutual

This article was originally published in The Tan Sheet & The Rose Sheet

Executive Summary

A ruling for RB n Pennsylvania federal court comes as it girds for increased competition from additional guaifenesin expectorant formulations that are the equivalents of Mucinex brand products and that Perrigo is marketing under license from manufacturer Allergan.

You may also be interested in...



Mutual Alleges Mucinex Monopoly In Extended-Release Guaifenesin

Mutual Pharmaceutical alleges in an antitrust suit that RB attempts to monopolize the extended-release guaifenesin OTC category with its Mucinex product. The suit says Mutual has lost “tens of millions” due to RB's failure to honor a contract to supply an “authorized generic” of the product.

Hemp Supplement Sales Continue In US Without FDA Acknowledgement As Lawful Products

Decision, explained by Principal Deputy Commissioner Woodcock, turns page on FDA’s 2019 announcement, after hemp was de-scheduled in 2018 farm bill, it would consider rulemaking for lawful use of hemp in supplements.

Improving US FDA Food Programs Starts At Top, Former Senior Agency Officials Say

Former acting commissioner Stephen Ostroff and Sharon Lindan Mayl, previously a senior advisor to FDA commissioner on food programs, say Reagan-Udall report was accurate in finding that establishing food program leadership with defined authorities is key to improving the programs, which include regulation of supplement manufacturing and marketing.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS123013

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel